semaglutide covered by medi-cal 🚨 California Alert: Coverage for Obesity Medications at Risk Just two years after began covering FDA-approved GLP-1 medications for obesity, that coverage is set to end in January 2026 — a Medicaid Coverage of and Spending

Its a question our team at Real Peptides hears all the time

No doctors visit required, no insurance required

Through comprehensive assessments, ongoing monitoring, and compassionate care, our team supports patients with clear, evidence-based recommendations designed to promote safety, sustainability, and long-term wellness

This mix might not be suitable for people with low fasting glucose levels or those taking insulin or sulfonylureas

Microplastic sources, formation, toxicity and remediation: a review

Despite this potential, given the known long-term benefit of lowering hemoglobin A1c in preventing DR progression, there does not appear to be any contraindication to initiating GLP-1/GIP agonist therapy with appropriate ocular monitoring